Figures computed from official regulatory filings — .
Analysttarget 2.02 USD (+106%)
Ownershipinsiders 18.09% · institutions 4.08% · short 2.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ABVC BIOPHARMA, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
17 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Stolz Kevin Patrick | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | Unusual size |
| SEC |
| Krotine Frank Thomas | AwardD (derivative) | $60K | SEC |
| Ramsey Sally Judith | AwardD (derivative) | $420K | SEC |
| Stolz Kevin Patrick | AwardD (derivative) | $10K | SEC |
| IANNOTTI DANIEL V | AwardD (derivative) | $60K | SEC |
| Crockett Robert G | AwardD (derivative) | $360K | SEC |
| Juliano James | AwardD (derivative) | $10K | SEC |
| Stromback Richard Dean | Sell | $4M | SEC |
| Stromback Richard Dean | BuyD (derivative) | $20K | First in 12mo | SEC |
| Nirta Joseph | Buy | $520 | conv 79First in 12mo | SEC |
| Nirta Joseph | Buy | $1.5K | conv 54 | SEC |
| Nirta Joseph | AwardD (derivative) | $104K | SEC |
| IANNOTTI DANIEL V | AwardD (derivative) | $112.2K | SEC |
| Smith J.B.track record | BuyD (derivative) | $55K | SEC |
| Smith J.B.track record | BuyD (derivative) | $31K | SEC |
| Smith J.B.track record | Buy | $35.7B | conv 50Unusual size | SEC |
| Stromback Richard Dean | BuyD (derivative) | $6K | SEC |
| Stromback Richard Dean | BuyD (derivative) | $100.8 | First in 12mo | SEC |
| Crockett Robert G | Award | $341.7K | SEC |
| Krotine Frank Thomas | Award | $86.2K | SEC |
| IANNOTTI DANIEL V | Award | $35.7K | SEC |
| Smith J.B.track record | OtherD (derivative) | $100K | SEC |
| Smith J.B.track record | Buy | $9.6B | conv 34Unusual size | SEC |
| Smith J.B.track record | Buy | $9.6B | conv 34Unusual size | SEC |
| Smith J.B.track record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |